40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
View analysts' price targets and recommendations, and compare them with competitors.
$52.00
Lower upside than CVE's upside of 85.41%.
Buy
Better than CVE's analyst recommendation of Hold.
Analyze analyst forecasts for the company and compare them with competitors.
7.62B
The estimated revenue has increased from the previous period.
3.07B
The estimated EBITDA has increased from the previous period.
5.30
The estimated EPS has increased from the previous period.
1.70B
The estimated net income has increased from the previous period.
1.84B
The estimated EBIT has increased from the previous period.
588.20M
The estimated SG&A expenses have increased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
21.97B
Revenue has increased from the previous period.
15.56%
Revenue growth rate is unchanged from the previous period.
4.39B
EBITDA has increased from the previous period.
20.00%
EBITDA margin is unchanged from the previous period.
-66.29M
EBIT has decreased from the previous period.
-0.30%
EBIT margin is unchanged from the previous period.
4.46B
Depreciation has increased from the previous period.
233.29M
Total cash has increased from the previous period.
1.06%
Cash percentage is unchanged from the previous period.
3.13B
Receivables have increased from the previous period.
14.23%
Receivables percentage is unchanged from the previous period.
25.74M
Inventories have increased from the previous period.
0.12%
Inventory percentage is unchanged from the previous period.
1.01B
Accounts payable has increased from the previous period.
4.60%
Payables percentage is unchanged from the previous period.
-5.52B
Capital expenditure has increased from the previous period.
-25.11%
CapEx percentage is unchanged from the previous period.
12.06%
WACC is unchanged from the previous period.
16.87%
Cost of equity is unchanged from the previous period.
5.31%
Cost of debt is unchanged from the previous period.
2.64
Beta is unchanged from the previous period.
263.90M
Diluted shares outstanding is unchanged from the previous period.
6.68B
Total debt is unchanged from the previous period.
10.03B
Total equity is unchanged from the previous period.
16.71B
Total capital is unchanged from the previous period.
39.98%
Debt weighting is unchanged from the previous period.
60.02%
Equity weighting is unchanged from the previous period.
-60.63M
EBIAT has decreased from the previous period.
-1.41B
UFCF has decreased from the previous period.
0.50%
Long-term growth rate is unchanged from the previous period.
-12.22B
Terminal value is unchanged from the previous period.
-10.90B
Enterprise value is unchanged from the previous period.
6.68B
Net debt is unchanged from the previous period.
-17.58B
Equity value is unchanged from the previous period.
-66.63
Equity value per share is unchanged from the previous period.
